This could only be true if the majority of the healthcare spending diff came from payments to pharma/health dev cos, right? Do you know whether that's the case?

If we're paying more for nurse salaries, hospital administration, insurance company bureaucracy, and ineffective procedures near end-of-life with low probability of success, it's unlikely the cost diff is mainly due to "subsidizing innovation."